Literature DB >> 287570

An initial report of a phase-III trial comparing vindesine and vincristine for acute lymphocytic leukemia of childhood.

W Krivit, R Chilcote, A Pyesmany, J Anderson, D Hammond.   

Abstract

The initial results from the Children's Cancer Study Group (CCSG) study on vindesine are the subject of this report. Vindesine was shown to be active in the treatment of acute lymphocytic leukemia (ALL) in children in a phase-II clinical trial conducted by the CCSG. A phase-II trial is now in progress. The aim of this is to compare the use of vincristine and of vindesine with reference to induction rate, toxicity, and cross-resistance.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 287570     DOI： 10.1007/bf00257193

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  1 in total

1.  Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.

Authors:  G Mathé; J L Misset; F De Vassal; J Gouveia; M Hayat; D Machover; D Belpomme; J L Pico; L Schwarzenberg; P Ribaud; M Musset; C Jasmin; L De Luca
Journal:  Cancer Treat Rep       Date:  1978-05
  1 in total
  2 in total

1.  Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.

Authors:  B T Hill; R D Whelan
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 2.  Childhood acute lymphoblastic leukaemia: a review.

Authors:  M L Willoughby
Journal:  J R Soc Med       Date:  1982-06       Impact factor: 18.000
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.